Inosine

Inosine

SCHEMBL5066239

O=c1cc[nH]c(=O)[nH]1.OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 6/20 0.56
ADORA3 P0DMS8 2/20 0.56
MAPK1 P28482 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
DPP4 P27487 1/20 0.56
MEN1 O00255 1/20 0.56
SLC28A1 O00337 1/20 0.56
MAP3K7 O43318 1/20 0.56
SLC28A2 O43868 1/20 0.56
GAPDH P04406 1/20 0.56
ADORA2A P29274 1/20 0.56
ADORA2B P29275 1/20 0.56
ADORA1 P30542 1/20 0.56
STAT6 P42226 1/20 0.56
PI4KA P42356 1/20 0.56
KMT2A Q03164 1/20 0.56
PI4K2B Q8TCG2 1/20 0.56
DOT1L Q8TEK3 1/20 0.56
PI4K2A Q9BTU6 1/20 0.56
SLC28A3 Q9HAS3 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adenosine SCHEMBL17363794 0.90 ADORA3 (0.72) SLC29A1ADORA3MAPK1SMN1; SMN2DPP4
Inosine SCHEMBL23209720 0.87 SLC29A1 (0.47) SLC29A1ADORA3MAPK1SMN1; SMN2DPP4
Inosine SCHEMBL222073 0.86 SLC29A1 (0.67) SLC29A1ADORA3MAPK1SMN1; SMN2DPP4
Inosine SCHEMBL298755 0.85 SLC29A1 (0.75) SLC29A1ADORA3MAPK1SMN1; SMN2DPP4
Inosine SCHEMBL18653532 0.85 SLC29A1 (0.75) SLC29A1ADORA3MAPK1SMN1; SMN2DPP4
Inosine SCHEMBL20138477 0.85 SLC29A1 (0.75) SLC29A1ADORA3MAPK1SMN1; SMN2DPP4
Inosine SCHEMBL4110068 0.85 SLC29A1 (0.75) SLC29A1ADORA3MAPK1SMN1; SMN2DPP4
Inosine SCHEMBL330178 0.85 SLC29A1 (0.75) SLC29A1ADORA3MAPK1SMN1; SMN2DPP4
Inosine SCHEMBL2046912 0.85 SLC29A1 (0.75) SLC29A1ADORA3MAPK1SMN1; SMN2DPP4
Inosine SCHEMBL6748954 0.85 SLC29A1 (0.75) SLC29A1ADORA3MAPK1SMN1; SMN2DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006029081-A2 NUCLEOSIDE-LIPID CONJUGATES, THEIR METHOD OF PREPARATION AND USES THEREOF NEOPHARM, INC. (US) 2006-03-16 WO claimed
US-20240148663-A1 PEG LIPIDS AND LIPID NANOPARTICLES GENEVANT SCIENCES GMBH (CH) 2024-05-09 US disclosed
US-20080274454-A1 Reversible and Chemically Programmable Micelle Assembly With Dna Block-Copolymer Amphiphiles NATIONAL SCIENCE FOUNDATION 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148663-A1 PEG LIPIDS AND LIPID NANOPARTICLES NPC1L1, LDLR, NPC1 SLC29A1 829/4885ADORA3 3573/4885MAPK1 1176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.